ARTICLE | Company News
Valeant sales and marketing update
April 27, 2017 9:07 PM UTC
Valeant priced psoriasis treatment Siliq brodalumab at a wholesale acquisition cost (WAC) of $3,500 per month, which it said is the lowest for a marketed injectable biologic psoriasis treatment. Competitor Humira adalimumab from AbbVie Inc. (NYSE:ABBV, Chicago, Ill.) has a monthly WAC of about $4,800. Cosentyx secukinumab from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and Enbrel etanercept from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) have monthly WACs of $4,308 and $4,422, respectively, according to the Red Book.
Of the four, Siliq is the only one that includes a boxed warning of suicidal ideation and behavior on its U.S. label...
BCIQ Company Profiles